Drugs / GW766944
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01160224 Comparator | Sep 2010 → Aug 2011 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GW766944 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01160224 ↗ |
| Action | Inhibit | “inhibition of the CCR3 receptor” NCT01160224 ↗ |
| Route | Oral | “Oral GW766944” NCT01160224 ↗ |
| Target | CCR3 | “antagonist of the human CC chemokine receptor-3 (CCR3)” NCT01160224 ↗ |